Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SABSW | US
0.00
4.02%
Healthcare
Biotechnology
30/06/2024
18/10/2024
0.05
0.05
0.05
0.05
SAB Biotherapeutics Inc. a clinical-stage biopharmaceutical company engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185 a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176 a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases such as COVID-19 and influenza immune system disorders comprising type 1 diabetes organ transplantation and cancer. The company was founded in 2014 and is based in Miami Beach Florida.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
168.9%1 month
267.8%3 months
312.6%6 months
329.6%0.13
-
-
0.12
0.09
-
-
-
-40.91M
-
-
-
-3.88K
-
207.70
-122.49
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.02
Range1M
0.03
Range3M
0.03
Rel. volume
0.14
Price X volume
175.79
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.91 | 0 | 3.70% | n/a | |
Viking Therapeutics Inc | VKTX | Biotechnology | 65.8 | 0 | 1.83% | n/a | |
VIRACTA THERAPEUTICS INC | VIRX | Biotechnology | 0.2298 | 0 | 3.14% | n/a | |
VINC | VINC | Biotechnology | 0.38 | 0 | 0.66% | n/a | |
Vigil Neuroscience Inc. Common Stock | VIGL | Biotechnology | 3.96 | 0 | -0.75% | n/a | |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5.65 | 0 | 3.48% | n/a | |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 41.16 | 0 | 3.18% | n/a | |
Veracyte Inc | VCYT | Biotechnology | 34.44 | 0 | 0.38% | n/a | |
Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 2.53 | 0 | 0.40% | n/a | |
Vericel Corporation | VCEL | Biotechnology | 41.66 | 0 | 2.43% | n/a |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4801 | 0 | -10.26% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.045 | 0 | -2.34% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.82 | 0 | 1.93% | n/a | |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | - | 0.53 | - |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | 0.13 | 40.42 | Cheaper |
Price to Book | - | 15.30 | - |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 312.57 | 72.92 | Riskier |
Debt to Equity | 0.12 | -1.24 | Expensive |
Debt to Assets | 0.09 | 0.25 | Cheaper |
Market Cap | - | 3.78B | - |